List view / Grid view
9 January 2025 | By Eurofins DiscoverX
Discover innovative and validated solutions for developing obesity therapeutics. These solutions enable effective screening, characterisation, and potency testing for commercial lot release of novel drugs targeting GPCRs, including GLP-1, GIP, and glucagon receptors.
A study from the University of Alabama at Birmingham reveals that HIF1α plays a crucial role in enabling T cells to kill tumour cells under low-oxygen conditions, providing a potential solution to resistance in immune checkpoint blockade (ICB) therapies.
The LiCellGrow cell expansion system enables real-time metabolic monitoring and automated culture optimisation to accelerate cell and gene therapy manufacturing.
Find out how Tessera's latest advancements in gene editing bring promising solutions to treat sickle cell disease.
Find out how in vivo cell therapies could transform cancer treatment by providing faster, more affordable, and accessible options for more patients.
Nektar Therapeutics' NKTR-255 improves CAR-T therapy outcomes in lymphoma patients. Find out how this development could impact cancer treatment.
We had the privilege of talking to Veerle d’Haenens, General Manager, Global Therapy Innovations at Terumo Blood and Cell Technologies. Her successful career has been driven by her creativity, expertise and passion, and she advises women who are aspiring to STEM roles to always think big.
New insights into the role of SUMOylation in the brain could lead to new targeted therapies for neurodegenerative conditions.
Developing cell therapies solely with healthy donor material can jeopardise clinical outcomes, introducing risks ranging from faulty preclinical data to manufacturing failures. We spoke to Priya Baraniak, CBO at OrganaBio, who advocates for early integration of diseased donor material, improved biobanking infrastructure, and cross-industry collaboration to develop more effective, patient-relevant…
Sphere Fluidics have developed the Cyto-Mine® Chroma platform, which provides multiplexing and greater assay flexibility, reducing timelines and cost.
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
In this Q&A, Dalip Sethi, scientific lead for Terumo Blood and Cell Technologies, Cell Therapy Technologies and Innovation portfolio, discusses the integration of AI into CGT manufacturing processes to enhance operational efficiency and accelerate treatment access. He also elucidates the strategies that are being considered to overcome hurdles when implementing…
Vittoria Biotherapeutics is pioneering a novel form of CAR-T therapy for T-cell lymphoma using CRISPR gene editing. Here, co-founders Nicholas Siciliano and Marco Ruella explain how their approach promises to overcome tumour resistance, while also offering hope for new ways to treat solid cancers.
Resolution Therapeutics is pioneering a novel approach to the treatment of chronic liver disease – by engineering the patient’s own macrophages to include regenerative properties. Cliff Brass, Chief Medical Officer at Resolution Therapeutics, explains how the aim is to reduce inflammation, improve liver function, and ultimately eliminate the need for…
Researchers showed that internal stress, induced by active cell behaviours, shapes the Drosophila wing disc pouch during eversion.
